• Icosavax raises funding to advance RSV/hMPV vaccine programme pharmaceutical-technology
    April 08, 2021
    Icosavax has raised $100m through a Series B financing round to support the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine programme through initial clinical studies.
PharmaSources Customer Service